



# SAFETY DATA SHEET

Revision date: 20-Nov-2018

Version: 4.1

Page 1 of 12

## 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

### Product Identifier

**Material Name:** Disopyramide Phosphate Extended-Release Capsules

**Trade Name:** Norpace CR

**Chemical Family:** Mixture

### Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

**Intended Use:** Pharmaceutical product used as anti-arrhythmic

### Details of the Supplier of the Safety Data Sheet

**Pfizer Inc**  
**Pfizer Pharmaceuticals Group**  
235 East 42nd Street  
New York, New York 10017  
1-800-879-3477

**Pfizer Ltd**  
**Ramsgate Road**  
**Sandwich, Kent**  
**CT13 9NJ**  
**United Kingdom**  
**+00 44 (0)1304 616161**

**Emergency telephone number:**

**CHEMTREC (24 hours): 1-800-424-9300**

**Contact E-Mail:** pfizer-MSDS@pfizer.com

**Emergency telephone number:**

**International CHEMTREC (24 hours): +1-703-527-3887**

## 2. HAZARDS IDENTIFICATION

### Classification of the Substance or Mixture

#### GHS - Classification

Acute Oral Toxicity: Category 4

Reproductive Toxicity: Category 1B

### Label Elements

**Signal Word:** Danger

**Hazard Statements:** H302 - Harmful if swallowed  
H360FD - May damage fertility. May damage the unborn child.

**Precautionary Statements:** P202 - Do not handle until all safety precautions have been read and understood  
P264 - Wash hands thoroughly after handling  
P270 - Do not eat, drink or smoke when using this product  
P281 - Use personal protective equipment as required  
P301+ P312 - IF SWALLOWED: Call a POISON CENTRE or doctor/physician if you feel unwell  
P330 - Rinse mouth  
P308 + P313 - IF exposed or concerned: Get medical attention/advice  
P405 - Store locked up  
P501 - Dispose of contents/container in accordance with all local and national regulations

## SAFETY DATA SHEET

**Material Name: Disopyramide Phosphate Extended-Release Capsules**  
**Revision date: 20-Nov-2018**

**Page 2 of 12**

**Version: 4.1**



**Other Hazards**

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

**Note:**

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

### 3. COMPOSITION / INFORMATION ON INGREDIENTS

**Hazardous**

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Disopyramide Phosphate	22059-60-5	244-756-1	Acute Tox.4 (H302) Repr.1B (H360Fd)	100 / 150 mg ***
Talc (non-asbestiform)	14807-96-6	238-877-9	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	*
Corn Starch	9005-25-8	232-679-6	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Lactose	63-42-3	200-559-2	Not Listed	*
Ethylcellulose	9004-57-3	Not Listed	Not Listed	*
Shellac	9000-59-3	232-549-9	Not Listed	*
FD&C Yellow No. 6; (Sunset yellow)	2783-94-0	220-491-7	Not Listed	*
D & C yellow No. 10	8004-92-0	Not Listed	Not Listed	*
FD & C Blue No. 1	3844-45-9	223-339-8	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	*
Sucrose	57-50-1	200-334-9	Not Listed	*

**Additional Information:**

\*\*\* per tablet/capsule/lozenge/suppository

\* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

**For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16**

### 4. FIRST AID MEASURES

**Description of First Aid Measures**

**Eye Contact:**

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 3 of 12

Version: 4.1

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of Exposure:** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

**Medical Conditions Aggravated by Exposure:** None known

### Indication of the Immediate Medical Attention and Special Treatment Needed

**Notes to Physician:** None

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

### Special Hazards Arising from the Substance or Mixture

**Hazardous Combustion Products:** Formation of toxic gases is possible during heating or fire.

**Fire / Explosion Hazards:** Not applicable

### Advice for Fire-Fighters

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

## 6. ACCIDENTAL RELEASE MEASURES

### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

### Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### Methods and Material for Containment and Cleaning Up

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

**Additional Consideration for Large Spills:** Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

## 7. HANDLING AND STORAGE

### Precautions for Safe Handling

Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 4 of 12

Version: 4.1

### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.  
Specific end use(s): Pharmaceutical drug product

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

### Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

#### Disopyramide Phosphate

Pfizer OEL TWA-8 Hr: 250µg/m<sup>3</sup>

#### Talc (non-asbestiform)

ACGIH Threshold Limit Value (TWA)	2 mg/m <sup>3</sup>
Australia TWA	2.5 mg/m <sup>3</sup>
Austria OEL - MAKs	2 mg/m <sup>3</sup>
Belgium OEL - TWA	2 mg/m <sup>3</sup>
Bulgaria OEL - TWA	1.0 fiber/cm <sup>3</sup>
	6.0 mg/m <sup>3</sup>
	3.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	2.0 mg/m <sup>3</sup>
Denmark OEL - TWA	0.3 fiber/cm <sup>3</sup>
Finland OEL - TWA	0.5 fiber/cm <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
	2 mg/m <sup>3</sup>
Hungary OEL - TWA	2 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	0.8 mg/m <sup>3</sup>
Lithuania OEL - TWA	2 mg/m <sup>3</sup>
	1 mg/m <sup>3</sup>
Netherlands OEL - TWA	0.25 mg/m <sup>3</sup>
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
Poland OEL - TWA	4.0 mg/m <sup>3</sup>
	1.0 mg/m <sup>3</sup>
Portugal OEL - TWA	2 mg/m <sup>3</sup>
Romania OEL - TWA	2 mg/m <sup>3</sup>
Slovakia OEL - TWA	2 mg/m <sup>3</sup>
	10 mg/m <sup>3</sup>
Slovenia OEL - TWA	2 mg/m <sup>3</sup>
Spain OEL - TWA	2 mg/m <sup>3</sup>
Sweden OEL - TWAs	2 mg/m <sup>3</sup>
	1 mg/m <sup>3</sup>
Switzerland OEL -TWAs	2 mg/m <sup>3</sup>

#### Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Austria OEL - MAKs	5 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Denmark OEL - TWA	6 mg/m <sup>3</sup>
Estonia OEL - TWA	5 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 5 of 12

Version: 4.1

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
Latvia OEL - TWA	10 mg/m <sup>3</sup>
Lithuania OEL - TWA	5 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup>
Poland OEL - TWA	10.0 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Romania OEL - TWA	10 mg/m <sup>3</sup>
Russia OEL - TWA	10 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Sweden OEL - TWAs	5 mg/m <sup>3</sup>
Switzerland OEL -TWAs	3 mg/m <sup>3</sup>
Vietnam OEL - TWAs	6 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>

#### Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Estonia OEL - TWA	10 mg/m <sup>3</sup>
France OEL - TWA	10 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
Latvia OEL - TWA	5 mg/m <sup>3</sup>
Lithuania OEL - TWA	10 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Slovakia OEL - TWA	6 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>

#### Corn Starch

ACGIH Threshold Limit Value (TWA)	10 mg/m <sup>3</sup>
Australia TWA	10 mg/m <sup>3</sup>
Belgium OEL - TWA	10 mg/m <sup>3</sup>
Bulgaria OEL - TWA	10.0 mg/m <sup>3</sup>
Czech Republic OEL - TWA	4.0 mg/m <sup>3</sup>
Greece OEL - TWA	10 mg/m <sup>3</sup>
	5 mg/m <sup>3</sup>
Ireland OEL - TWAs	10 mg/m <sup>3</sup>
	4 mg/m <sup>3</sup>
OSHA - Final PELS - TWAs:	15 mg/m <sup>3</sup>
Portugal OEL - TWA	10 mg/m <sup>3</sup>
Slovakia OEL - TWA	4 mg/m <sup>3</sup>
Spain OEL - TWA	10 mg/m <sup>3</sup>
Switzerland OEL -TWAs	3 mg/m <sup>3</sup>

#### Analytical Method:

Analytical method available for Disopyramide Phosphate. Contact Pfizer Inc for further information.

#### Exposure Controls

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 6 of 12

Version: 4.1

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

<b>Engineering Controls:</b>	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
<b>Personal Protective Equipment:</b>	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
<b>Hands:</b>	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.)
<b>Eyes:</b>	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.)
<b>Skin:</b>	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)
<b>Respiratory protection:</b>	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>Physical State:</b>	Capsule	<b>Color:</b>	White / Light green or Brown / light green
<b>Odor:</b>	No data available.	<b>Odor Threshold:</b>	No data available.
<b>Molecular Formula:</b>	Mixture	<b>Molecular Weight:</b>	Mixture
<b>Solvent Solubility:</b>	No data available		
<b>Water Solubility:</b>	No data available		
<b>pH:</b>	No data available.		
<b>Melting/Freezing Point (°C):</b>	No data available		
<b>Boiling Point (°C):</b>	No data available.		
<b>Partition Coefficient: (Method, pH, Endpoint, Value)</b>			
<b>Disopyramide Phosphate</b>	No data available		
<b>Corn Starch</b>	No data available		
<b>FD &amp; C Red No. 3 (E 127)</b>	No data available		
<b>Gelatin</b>	No data available		
<b>Talc (non-asbestiform)</b>	No data available		
<b>Titanium dioxide</b>	No data available		
<b>FD &amp; C Blue No. 1</b>	No data available		
<b>D &amp; C yellow No. 10</b>	No data available		

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 7 of 12

Version: 4.1

### 9. PHYSICAL AND CHEMICAL PROPERTIES

FD&C Yellow No. 6; (Sunset yellow)

No data available

**Sucrose**

No data available

**Ethylcellulose**

No data available

**Shellac**

No data available

**Lactose**

No data available

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available

**Vapor Pressure (kPa):** No data available

**Vapor Density (g/ml):** No data available

**Relative Density:** No data available

**Viscosity:** No data available

**Flammability:**

**Autoignition Temperature (Solid) (°C):** No data available

**Flammability (Solids):** No data available

**Flash Point (Liquid) (°C):** No data available

**Upper Explosive Limits (Liquid) (% by Vol.):** No data available

**Lower Explosive Limits (Liquid) (% by Vol.):** No data available

### 10. STABILITY AND REACTIVITY

**Reactivity:** No data available

**Chemical Stability:** Stable under normal conditions of use.

**Possibility of Hazardous Reactions**

**Oxidizing Properties:** No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

**Hazardous Decomposition Products:** No data available

### 11. TOXICOLOGICAL INFORMATION

**Information on Toxicological Effects**

**General Information:** The information included in this section describes the potential hazards of the individual ingredients.

**Long Term:** Repeat-dose studies in animals have shown a potential to cause adverse effects on the developing fetus.

**Known Clinical Effects:** Clinical use of this drug has caused dry mouth, blurred vision, difficulty with urination lack of urination, constipation, increased heart rate (tachycardia), irregular heartbeat (cardiac arrhythmia), decrease in blood pressure (hypotension). Can produce impotence and other sexual disturbances in men.

**Acute Toxicity: (Species, Route, End Point, Dose)**

**Disopyramide Phosphate**

Rat Oral LD 50 333-580 (F) mg/kg

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 8 of 12

Version: 4.1

### 11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 333-888 (M)mg/kg

#### FD & C Red No. 3 (E 127)

Rat Oral LD50 1840 mg/kg  
Mouse Oral LD50 1264mg/kg

#### Talc (non-asbestiform)

Rat Oral LD50 > 1600 mg/kg

#### Titanium dioxide

Rat Oral LD50 > 7500 mg/kg  
Rat Subcutaneous LD50 50 mg/kg

#### D & C yellow No. 10

Rat Oral LD50 2000 mg/kg

#### FD&C Yellow No. 6; (Sunset yellow)

Rat Oral LD50 > 10,000 mg/kg  
Mouse Oral LD50 > 6,000mg/kg

#### Sucrose

Rat Oral LD50 29.7 g/kg

#### Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

#### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

##### Disopyramide Phosphate

4 Week(s)	Rat	Oral	300 mg/kg/day	LOAEL	Central nervous system
5 Week(s)	Dog	Intravenous	315 mg/kg/day	LOAEL	Central Nervous System
40 Week(s)	Rat		400 mg/kg/day	NOAEL	None identified
1 Year(s)	Dog		100 mg/kg/day	NOAEL	None identified
78 Week(s)	Rat		400 mg/kg/day	NOAEL	None identified

#### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

##### Disopyramide Phosphate

Reproductive & Fertility	Rat	250 mg/kg/day	NOAEL	No effects at maximum dose
Embryo / Fetal Development	Rat	250 mg/kg/day	LOAEL	Maternal Toxicity, Embryotoxicity, Fetotoxicity
Embryo / Fetal Development	Rabbit	60 mg/kg/day	LOAEL	Fetotoxicity

#### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

##### Disopyramide Phosphate

Bacterial Mutagenicity (Ames) *Salmonella* Negative

##### Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

#### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))



## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 9 of 12

Version: 4.1

### 11. TOXICOLOGICAL INFORMATION

#### Disopyramide Phosphate

Not specified Rat No route specified 400 NOEL Not carcinogenic

**Carcinogen Status:** See below

#### Talc (non-asbestiform)

**IARC:** Group 3 (Not Classifiable)

#### Titanium dioxide

**IARC:** Group 2B (Possibly Carcinogenic to Humans)

#### FD & C Blue No. 1

**IARC:** Group 3 (Not Classifiable)

#### FD&C Yellow No. 6; (Sunset yellow)

**IARC:** Group 3 (Not Classifiable)

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be avoided.

**Toxicity:** No data available

**Persistence and Degradability:** No data available

**Bio-accumulative Potential:** No data available

**Mobility in Soil:** No data available

### 13. DISPOSAL CONSIDERATIONS

**Waste Treatment Methods:** Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 10 of 12

Version: 4.1

### 15. REGULATORY INFORMATION

#### Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

##### Lactose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-559-2

##### Ethylcellulose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

##### Shellac

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-549-9

##### FD&C Yellow No. 6; (Sunset yellow)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	220-491-7

##### D & C yellow No. 10

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

##### Disopyramide Phosphate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present

## SAFETY DATA SHEET

Material Name: Disopyramide Phosphate Extended-Release  
Capsules  
Revision date: 20-Nov-2018

Page 11 of 12

Version: 4.1

### 15. REGULATORY INFORMATION

EU EINECS/ELINCS List	244-756-1
<b>FD &amp; C Blue No. 1</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	223-339-8
<b>Gelatin</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6
<b>Talc (non-asbestiform)</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	238-877-9
<b>Titanium dioxide</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen 9/2/2011 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5
<b>Sucrose</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9
<b>Corn Starch</b>	
CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	232-679-6

### 16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

## SAFETY DATA SHEET

**Material Name:** Disopyramide Phosphate Extended-Release  
Capsules  
**Revision date:** 20-Nov-2018

Page 12 of 12

Version: 4.1

---

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed  
Reproductive toxicity-Cat.1B; H360Fd - May damage fertility. Suspected of damaging the unborn child.

**Data Sources:** Publicly available toxicity information. Pfizer proprietary drug development information. Safety data sheets for individual ingredients.

**Reasons for Revision:** Updated Section 2 - Hazard Identification. Updated Section 11 - Toxicology Information.  
Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.  
Updated Section 8 - Exposure Controls / Personal Protection.

**Revision date:** 20-Nov-2018

**Prepared by:** Product Stewardship Hazard Communication  
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**